A Study of SI-6603 in Patients With Lumbar Disc Herniation
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2018
Price : $35 *
At a glance
- Drugs Condoliase (Primary)
- Indications Intervertebral disc displacement
- Focus Registrational; Therapeutic Use
- Sponsors Seikagaku Corporation
- 07 Nov 2017 Primary endpoint (Leg pain) has not been met, according to a Seikagaku Corporation media release.
- 07 Nov 2017 According to a Seikagaku Corporation media release, status changed from active, no longer recruiting to completed.
- 25 Nov 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.